ZMAb (Ebola)
A combination drug, ZMAb, is composed of equal parts of three monoclonal antibodies directed against the envelope glycoproteins of the Ebola virus. The pioneering work was conducted at the National Microbiology Laboratory (Winnipeg, Canada), through the Public Health Agency of Canada (PHAC). In completed primate studies using a highly lethal challenge, the ZMAb cocktail was able to provide 100% treatment survival when administered 3 days after challenge. Further, ZMAb treatment resulted in low viral loads, mild symptoms and no viral shedding of the challenge agent.
Availability: In Development
| Manufacturer |
| Defyrus, Inc. |
| Product Name |
| ZMAb (Ebola) |
| Detection Category |
| Biological |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| A combination drug, ZMAb, is composed of equal parts of three monoclonal antibodies directed against the envelope glycoproteins of the Ebola virus. The pioneering work was conducted at the National Microbiology Laboratory (Winnipeg, Canada), through the Public Health Agency of Canada (PHAC). In completed primate studies using a highly lethal challenge, the ZMAb cocktail was able to provide 100% treatment survival when administered 3 days after challenge. Further, ZMAb treatment resulted in low viral loads, mild symptoms and no viral shedding of the challenge agent. |
| Availability |
| In Development |
| Technology Readiness Level (TRL) |
| 7 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Transportability |
| Pocket Size |
| Live Agent Tested |
| Yes; Ebola |
| Operating Time |
| Immediate post-exposure use |
| Training Required |
| <1 day training |
